Antares Pharma announced 12 week efficacy and 52 week safety results from the phase III clinical study (QST-13-003) evaluating testosterone...
-Antares Pharma, Inc. announced the approval of Xyosted (testosterone enanthate) injection by the FDA Xyosted is the first FDA approved...
Antares Pharma has announced that it had submitted a New Drug Application (NDA) to the FDA for QuickShot Testosterone (QST),...